Drug Trial Radar · NCT06957821
Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Jun 2027
Primary completion
Jul 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- May 5, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Active inflammation plays a key role in causing Coronary Artery Disease (CAD) and Peripheral Arterial Disease (PAD). Since inflammation is so important in how these diseases start, are diagnosed, and treated, being able to see it clearly in each patient could lead to more personalized and effective care - and may help prevent heart attacks. Right now, there's no imaging technology available to clearly see inflammation inside the coronary arteries. The investigators hope to learn how an imaging drug; called LUMISIGHT (Pegulicianine) can help detect inflammation in blood vessels compared with saline. If the investigators find out that LUMISIGHT is active in humans, the investigators might be able to use it for detecting plaque risk in the future.
Conditions
- Carotid Artery Diseases
- Peripheral Arterial Disease
Interventions
PegulicianineDrug
Pegulicianine (LUMISIGHT) Inflammatory activity
PlaceboOther
Control group for the study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demonstrate lumisight fluorescence activity in lumisight cohort vs controlsTime frame: 2-6 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.